anti-flt3 car-t
Cell therapyexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 19, 2021 (NCT05023707)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Receptor-type tyrosine-protein kinase FLT3Immunity, passive
FLT3 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06786533 | Phase 1 | Jan 23, 2025 | Hemogenyx Pharmaceuticals LLC |
| NCT05562024 | Phase 1 | Dec 15, 2022 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., Tianjin Medical University |
| NCT05432401 | Early Phase 1 (Phase 1) | Jun 9, 2022 | Huazhong University of Science and Technology, PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| NCT05023707 | Phase 1/Phase 2 (Phase 2) | Oct 19, 2021 | Huai'an Second People's Hospital, Nanjing Medical University, Nanjing University, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Soochow University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | For profit | 3 | 2 | 2 | 2021 |
| Hemogenyx Pharmaceuticals LLC | For profit | 1 | 1 | 1 | 2025 |
| Huai'an Second People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Nanjing University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Soochow University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
8 organizations
Page 1 / 1